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The addition of 5-ﬂuorouracil (5-FU) or its prodrug capecitabine to radiotherapy (RT) is a
standard approach in the neo-adjuvant treatment of patients with rectal tumors extending
beyond themuscularis propria (stage II) and/orwith clinical evidence of regional lymph node
metastases (stage III). According to European randomized trials, the combined treatment
modality resulted in favorable local control rates as compared with radiotherapy (RT) alone,
but no improvement was found regarding the occurrence of distant metastases or overall
survival. In an effort to further enhance the response rates and to decrease the high inci-
dence of distantmetastases in locally advanced rectal cancer patients, the addition of other
chemotherapeutical drugs and biologic agents as radiation sensitizers to neo-adjuvant 5-FU
based chemoradiotherapy (CRT) has been recently investigated. The role of those agents
is however questionable as ﬁrst results from phase III data do not show improvement
on pathologic complete remission and circumferential resection margin negative resection
rates as compared to 5-FU based CRT, nevertheless an increased toxicity.
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INTRODUCTION
Over the past decades, considerable advances have been made in
the use of long-course CRT in rectal cancer. Based on a num-
ber of pivotal studies in the US which demonstrated positive
effects on local control (LC) and overall survival (OS) with the
addition of RT and chemotherapy following surgical resection in
locally advanced rectal cancer, most clinicians initially favored the
use of adjuvant 5-FU based CRT (Krook et al., 1991; Wolmark
et al., 2000). Theoretically, RT should be delivered neo-adjuvantly
rather than adjuvantly since poor cell oxygenation in the heal-
ing tumor bed potentially decreases radiosensitivity. Secondary,
as the small bowel is not trapped in the pelvic bay by postop-
erative adhesions, fewer enteric complications are expected with
neo-adjuvant RT, where moving loops of small bowel are located
on different positions from day to day. Lastly, neo-adjuvant down-
staging may positively inﬂuence the surgical margin status and
sphincter preservation rate. Strong evidence of the superiority of
neo-adjuvant to adjuvant CRT in stage II/III rectal cancer patients
undergoing total mesorectal excision (TME) was provided by the
5-year results of the randomized German Rectal Cancer Study
(CAO/ARO/AIO 94), with a signiﬁcant lower rate of pelvic recur-
rence in favor of neo-adjuvant CRT as compared to adjuvant
CRT (6 versus 13%). Moreover, the data also showed signiﬁ-
cant lower rates of toxicity with the use of neo-adjuvant CRT
(Sauer et al., 2004). The addition of 5-FU to long-course neo-
adjuvant RT is considered standard of care in locally advanced
rectal cancer by the evidence of two important phase III trials,
EORTC 22921 and FFCD 9203, which demonstrated the advan-
tages of neo-adjuvant 5-FU based CRT over RT alone with respect
to pathologic complete remission (pCR) and LC, but not with
respect to the rate of sphincter-sparing surgery, occurrence of dis-
tant metastases, or OS (Bosset et al., 2006; Gérard et al., 2006).
Those ﬁndings led to a shift in the European andUSpolicy of adju-
vant CRT to neo-adjuvant 5-FU CRT, which is now standard of
care in stage II/III rectal cancer. Recently, a non-inferiority phase
III trial of the Mannheimer Arbeitsgruppe für Gastrointestinale
Tumoren (MARGIT) which compared capecitabine to 5-FU in
(neo-)adjuvant CRT of locally advanced rectal cancer provided a
growing body of evidence for using capecitabine (Hofheinz et al.,
2011). Besides a non-inferiority to 5-FU regarding 5-year OS (76
versus 67% with 5-FU, p< 0.05), patients receiving capecitabine
experienced equal LC. In concordance with the toxicity proﬁle of
capecitabine in the adjuvant treatment of colorectal cancer (CRC),
less leukopenia but more hand-foot skin reactions and proctitis
were recorded compared to 5-FU (Hofheinz et al., 2011). In view
of its advantageous administration proﬁle (no need for catheter
placement and infusion pump), those encouraging ﬁndings may
impact the current standard of administrating 5-FU intravenously
during neo-adjuvant RT. Despite those improvements, more than
one third of the patients undergoing curative treatment of rec-
tal cancer have distant recurrence of this disease. In an effort to
further improve the pCR rate, which is considered as a surro-
gate end point for LC and OS, and to decrease the high incidence
of distant recurrences, several phase II and III trials investigated
in addition to neo-adjuvant 5-FU based CRT the use of induction
chemotherapy andmulti-agent systemic therapybymeans of other
chemotherapeutical drugs (oxaliplatin) or biologic agents such as
cetuximab and bevacizumab, which are epidermal growth factor
receptor (EGFR) and vascular endothelial growth factor (VEGF)
directed monoclonal antibodies, respectively.
INDUCTION CHEMOTHERAPY
An attempt to enhance the outcome after neo-adjuvant CRT and
TME includes the concept of induction chemotherapy, which has
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been reported so far only in phase II setting (Chua et al., 2010;
Fernandez-Martos et al., 2010). A randomized phase II Span-
ish trial observed no differences in pCR and R0 resection rate
between patients receiving neo-adjuvant CRT with capecitabine
and oxaliplatin (CAPOX) and those receiving induction CAPOX
followed by CRT with CAPOX (Fernandez-Martos et al., 2010).
After a median follow-up of 39 months, similar 3-year disease-free
survival (DFS) and OS rates were recorded in the two treatment
arms (Fernandez-Martos et al., 2011). The EXPERT trial, carrying
out four cycles of neo-adjuvant CAPOX followed by concomi-
tant capecitabine based CRT prior to TME in magnetic resonance
imaging (MRI) deﬁned high-risk rectal cancer patients, reported a
promising 20% pCR and 4% R1 rate, with acceptable safety (Chua
et al., 2010). One should however notice the 9 clinically signiﬁ-
cant cardiotoxic events in 8 out of 77 enrolled patients, of which
4 patients died, before protocol amendment of this trial in Janu-
ary 2004 to exclude patients with recent cardiac morbidity (Chau
et al., 2006). Although the impressive number of early fatal events
in this trial is not observed in other studies evaluating the safety
of induction chemotherapy, acute toxicity is considerable with
reported rates of grade ≥3 acute diarrhea and lymphocytopenia
of 20 and 43%, respectively, according to a phase II study where
patients received one cycle of CAPOX followed by CAPOX based
CRT and surgery (Koeberle et al., 2008). Based on those phase II
data, induction chemotherapy does not seem to be safe and should
therefore not be recommended outside clinical trials.
ADDITION OF OXALIPLATIN TO NEO-ADJUVANT 5-FU
BASED CRT
Four randomized phase III studies, the Studio Terapia Adiu-
vante Retto (STAR)-01 trial, Prodige 2-ACCORD-12/405 trial, the
National Surgical Adjuvant Breast and Bowel Project (NSABP) R-
04 trial and the German CAO/ARO/AIO-04 trial evaluated the
tolerability and efﬁcacy of the addition of oxaliplatin to 5-FU
based CRT as neo-adjuvant treatment of locally advanced rec-
tal cancer (Gérard et al., 2010; Aschele et al., 2011; Roedel et al.,
2011; Roh et al., 2011). No improvement in the pCR rate was
noted as compared to 5-FU based CRT alone in the STAR-01 trial,
with reported rates of 16% in both arms (Aschele et al., 2011).
Furthermore, no differences in R0 resection rates circumferential
resection margin (CRM; >1 mm) were observed with the addi-
tion of oxaliplatin (93 versus 96%; Aschele et al., 2011). Longer
follow-up is needed in this study to assess the impact on the pri-
mary endpoint, OS. In similarity, the Prodige 2-ACCORD-12/405
trial displayed no differences in pCR (19 versus 14%, p = 0.09),
the primary endpoint, or CRM involvement (7.7 versus 12.7%,
p = 0.17) with the addition of oxaliplatin to capecitabine based
CRT (Gérard et al., 2010). Those ﬁndings were conﬁrmed by ﬁrst
results from the NSABP R-04 trial, randomizing 1680 rectal cancer
patients between four treatment groups: neo-adjuvant continuous
infusion 5-FU CRT with or without oxaliplatin or neo-adjuvant
capecitabine CRT with or without oxaliplatin, showing no differ-
ences in downstaging, sphincter preservation rate or pCR (Roh
et al., 2011). Primary endpoints of this study, DFS and OS, are
awaiting. The cumulative incidence of distant recurrence of 36%
in theneo-adjuvant armof theGermanRectalCancer Study (Sauer
et al., 2004) led to a comparison of this regimen to an arm that
incorporates oxaliplatin during both neo-adjuvant 5-FU CRT and
5-FU adjuvant chemotherapy in the German CAO/ARO/AIO-
O4 randomized phase III trial, which was powered to detect a
7% difference in 3-year DFS as primary endpoint (Roedel et al.,
2011). First results of this trial showed no signiﬁcant differences
in grade ≥3 acute toxicity (22% for 5-FU versus 23% for 5-
FU/oxaliplatin arm), rates of sphincter preserving surgery, and R0
resection, whereas a slight but signiﬁcant improvement was found
in terms of pCR with the addition of oxaliplatin (17 versus 13%,
p = 0.045; Roedel et al., 2011). It should be noticed that their reg-
imen, unlike the other trials, included a chemotherapy gap during
the third week of RT which may explain the similar toxicity rates
and improved compliance rates (Roedel et al., 2011). Additional
follow-up is however needed to report on the primary endpoint.
Recently, Gérard et al. (2012) presented the clinical outcomes after
amedian follow-up time of 36 months of the 598 patients included
in the Prodige 2-ACCORD-12/405 trial, and they observed no dif-
ferences in LC, DFS, or OS between the group of patients who
received neo-adjuvant CAPOX based CRT as compared to those
who underwent neo-adjuvant capecitabine CRT. Not surprisingly
with intensiﬁed multi-agent chemotherapy, side effects may be
enhanced signiﬁcantly. First results from the NSABP R-04 trial
displayed a more than twofold excessive risk of grade ≥3 diar-
rhea with the addition of oxaliplatin to 5-FU based CRT (Roh
et al., 2011). The STAR-01 and Prodige 2-ACCORD-12/405 trial
reported a signiﬁcant increase in grade ≥3 acute toxicity, with
reported rates of 25% in patients receiving oxaliplatin compared
to 8–11% for the groups receiving 5-FU based CRT alone (Gérard
et al., 2010; Aschele et al., 2011). Given the activity of oxaliplatin
in combination with 5-FU based chemotherapy in the adjuvant
and metastatic setting of colon cancer and the well established
radiosensitizing effects of another platinum-based drug, cisplatin,
in the treatment of lung cancer and cervical cancer, its clinical
additive effect to 5-FU based CRT in the neo-adjuvant setting
of rectal cancer is disappointing. Regarding its active launch into
clinical combined modality trials, with the ﬁrst phase I study of
oxaliplatin in neo-adjuvant CRT of rectal cancer already 11 years
ago (Freyer et al., 2001), solid biological data with respect to the
radiosensitizing activity of oxaliplatin are quite limited and not
conclusive. Only in abstract form, oxaliplatin was shown to sensi-
tize CRC cell cultures to radiation in vitro (Blackstock et al., 2000,
2002). In combinationwith 5-FU in vitro, exposure of humanCRC
cell line HT29 to oxaliplatin indicated synergistic effects to radia-
tion, whereas in vivo it failed to improve the growth inhibitory
response induced by fractionated radiation doses of 2 Gy plus
capecitabine in HT29 colorectal tumor xenografts (Folkvord et al.,
2008). On the basis of the scarcity of this preclinical evidence, fur-
ther experimental in vivo studies are warranted to determine the
radiosensitizing properties of oxaliplatin in neo-adjuvant CRT of
rectal cancer and to provide a strong preclinical knowledge which
is critical before moving on to further phase III trials. Moreover,
the primary goal in those phase III trials is of crucial concern in
the era of 5-FU based CRT, where local recurrences after TME are
already reported to occur in less than 5% of the patients and where
surrogate end points such as pCR are debatable. Given that one
third of the patients with resected rectal cancer develop metastatic
disease despite the very high LC after neo-adjuvant CRT and TME,
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the focus should be on the eradication of subclinical metastatic
disease. However, with current clinical end points such as DFS
and OS, the large number of patients to be enrolled and long time
period before analysis within phase III studies do not allow a quick
answer on the systemic efﬁcacy of a new medical treatment in the
neo-adjuvant setting of rectal cancer. In conclusion, the addition
of oxaliplatin to 5-FU based CRT cannot be considered a standard
approach in the neo-adjuvant management of locally advanced
rectal cancer, but the long-term follow-up data of those phase III
trials should be awaited.
CETUXIMAB
In a randomized phase II study, the EXPERT-C trial addressed the
addition of weekly cetuximab to the concept of induction CAPOX
and concurrent capecitabine CRT, as used in the EXPERT trial
(Chua et al., 2010), in high-risk rectal cancer patients (Dewdney
et al., 2011). No differences were found in pCR, progression-free
survival (PFS) and OS for the all treated population (Dewdney
et al., 2011). In subgroup analysis, KRAS and BRAF wild type
patients displayed signiﬁcantly improved 3-year OS with the addi-
tion of cetuximab once per week throughout treatment compared
to those who received induction chemotherapy and CRT alone (96
versus 81%, p = 0.04; Dewdney et al., 2011). Interestingly, there
was no signiﬁcant difference in pCR (7 versus 11%) in the wild
type patients receiving cetuximab compared to those not receiv-
ing cetuximab (Dewdney et al., 2011). The low pCR rate may
in part be explained by the eight patients displaying a pCR but
with insufﬁcient tissue for KRAS and BRAF analysis, of which six
patients received cetuximab. Grade 3+ skin rash was, as expected,
increased with the use of cetuximab as well as the rates of diar-
rhea in patients receiving cetuximab, the latter only during CRT
(Dewdney et al., 2011). In a pooled analysis of 10 phase I/II trials
incorporating cetuximab in neo-adjuvant CRT of rectal cancer, an
overall pCR rate and R1 resection rate of 9 and 7% were reported
(Glynne-Jones et al., 2010). Based on those ﬁrst results, adding
cetuximab to neo-adjuvant CRT does not seem to improve pCR,
with respect to an overall pCR rate of 13% seen after 5-FU based
CRT (Glynne-Jones et al., 2010). Possible reasons for the dis-
appointing results on the early endpoint of pCR include a less
crucial role for repopulation in adenocarcinoma of the rectum
in the presence of continuous exposure to 5-FU and RT (Brier-
ley et al., 1996; Glynne-Jones et al., 2010). In addition, cetuximab
could potentially abolish the additive effects of 5-FU by blockade
of S phase entry, as cells which fail to progress through S phase
do not accumulate additive effects from the combination of 5-
FU and radiation (Lawrence et al., 1996, 2003; Huang and Harari,
2000). The optimum sequence of cetuximab in addition to 5-FU
CRT remains unclear and should be explored before moving on
to phase III trials. Furthermore, biomarkers such as KRAS and
BRAF mutational status, which are predictive for lack of response
to anti-EGFR therapy in metastatic CRC, have to be integrated in
those trials, ﬁnally to help us in selecting out appropriate patients
which may beneﬁt from neo-adjuvant CRT in combination with
cetuximab.
BEVACIZUMAB
In a Phase I/II trial in rectal cancer patients receiving bevacizumab
and CRT, Willett et al. (2004) provided direct evidence of the
antivascular effect of anti-VEGF treatment by functional, cellular,
and molecular investigations. Brieﬂy, bevacizumab decreases the
tumor vascular density, tumor perfusion, tumor interstitial ﬂuid
pressure, and the number of viable circulating endothelial and
progenitor cells, which results into a signiﬁcant increase in apop-
tosis of cancer cells (Willett et al., 2004). Several phase I/II trials
reported on the feasibility of adding bevacizumab to 5-FU based
CRT in the neo-adjuvant setting of locally advanced rectal can-
cer, and provided encouraging pCR rates with moderate toxicity
(Willett et al., 2009; Crane et al., 2010). The reported incidence of
postoperative wound complications in up to 36% of the patients
is however concerning and consistent with other reports utiliz-
ing bevacizumab with CRT before a major surgical procedure
(Dipetrillo et al., 2012). Recently, a systematic review identiﬁed
between 2000 and 2011 15 trials which incorporated bevacizumab
in neo-adjuvant CRT and calculated a pooled pCR rate of 21%,
which is not superior than those reported with 5-FU based CRT
(Shaalan Beg et al., 2012). Taking into account the lack of phase
III data in the neo-adjuvant setting of rectal cancer, the similar
response rates as compared to 5-FU based CRT alone and the con-
siderable treatment-related toxicities, bevacizumab as a radiation
sensitizer in combination with 5-FU based CRT does not seem
to provide additional beneﬁts in the neo-adjuvant treatment of
locally advanced rectal cancer.
CONCLUSION
In conclusion, 5-FU based CRT still remains the standard of care
in the neo-adjuvant treatment of locally advanced rectal cancer.
Intensifying this regimen by the concept of induction chemother-
apy, concurrent multi-agent chemotherapy or the addition of
biologic agents does not seem to improve treatment efﬁcacy in
terms of pCR, sphincter preservation, or CRM negative resection
rate, and is therefore not recommended outside clinical trials in
locally advanced rectal cancer. The impact of those strategies on
the occurrence of distant metastases and OS remains unclear until
additional follow-up is achieved.
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